X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (31) 31
index medicus (29) 29
oncology (22) 22
hematology (20) 20
female (15) 15
aged (13) 13
antineoplastic agents - therapeutic use (12) 12
male (12) 12
middle aged (11) 11
treatment outcome (11) 11
article (9) 9
cancer (9) 9
protein kinase inhibitors - therapeutic use (9) 9
adult (8) 8
hematology, oncology and palliative medicine (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (8) 8
care and treatment (7) 7
imatinib (7) 7
leukemia (7) 7
therapy (7) 7
bone-marrow-transplantation (6) 6
myelofibrosis (6) 6
nilotinib (6) 6
tyrosine (6) 6
aged, 80 and over (5) 5
antineoplastic agents - administration & dosage (5) 5
antineoplastic agents - adverse effects (5) 5
benzamides (5) 5
chronic myelogenous leukemia (5) 5
chronic myeloid leukemia (5) 5
drug therapy (5) 5
efficacy (5) 5
imatinib mesylate (5) 5
medicine & public health (5) 5
prognosis (5) 5
pyrimidines - therapeutic use (5) 5
quality of life (5) 5
research (5) 5
dasatinib (4) 4
discontinuation (4) 4
disease-free survival (4) 4
geriatrics/gerontology (4) 4
hemic and lymphatic diseases (4) 4
international working group (4) 4
janus kinase 2 - antagonists & inhibitors (4) 4
myelodysplastic syndromes (4) 4
piperazines - therapeutic use (4) 4
primary myelofibrosis - drug therapy (4) 4
retrospective studies (4) 4
survival (4) 4
abridged index medicus (3) 3
adherence (3) 3
adults (3) 3
chronic myeloid-leukemia (3) 3
clinical trials as topic (3) 3
hematopoietic stem cells (3) 3
jak2 inhibitor (3) 3
janus kinase 2 - genetics (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - genetics (3) 3
medicine, general & internal (3) 3
mortality (3) 3
mutation (3) 3
myelodysplastic syndromes - therapy (3) 3
myeloid metaplasia (3) 3
myeloproliferative disorders - genetics (3) 3
myeloproliferative neoplasms (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
outcomes (3) 3
patients (3) 3
pharmacology & pharmacy (3) 3
phase-iii (3) 3
phenols (3) 3
philadelphia chromosome (3) 3
polycythemia-vera (3) 3
pregnancy (3) 3
pyrazoles - therapeutic use (3) 3
pyrimidines - administration & dosage (3) 3
quality-of-life (3) 3
recurrence (3) 3
remission induction (3) 3
safety (3) 3
stem cell transplantation (3) 3
tyrosine kinase inhibitor (3) 3
young adult (3) 3
acute myeloid-leukemia (2) 2
age (2) 2
anemia - etiology (2) 2
animals (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
arsenic trioxide (2) 2
azacitidine - administration & dosage (2) 2
azacitidine - adverse effects (2) 2
benzimidazoles - adverse effects (2) 2
benzimidazoles - therapeutic use (2) 2
bone marrow (2) 2
chemotherapy (2) 2
chronic (2) 2
chronic-phase (2) 2
clinical trials (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 496 - 508
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1757 - 1757
Background: The treatment paradigm of chronic lymphocytic leukemia (CLL) has changed significantly in the last decade with approval of multiple new targeted... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2208 - 2208
Background: This study assessed the clinical practice of US physicians managing patients with chronic myeloid leukemia (CML) with a focus on tyrosine-kinase... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5246 - 5246
Abstract Background The inflammatory and immune response in tumor microenvironment plays a critical role in cancer progression. Neutrophil-to-lymphocyte ratio... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2253 - 2253
Abstract The incidence of familial acute leukemias (AL) and myelodysplastic syndrome (MDS) in the adult population is not well characterized, though recent... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4362 - 4362
Abstract Introduction: Higher risk MDS is a serious disease associated with poor survival with hypomethylating agents (HMAs) the standard of care in patients... 
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 01/2014, Volume 20, Issue 2, pp. 490 - 498
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e19024 - e19024
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2605 - 2605
Background: Lintuzumab Ac225 is a radiolabeled anti-CD33 antibody with demonstrated single-agent activity in AML. The drug is composed of an alpha emitting... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 3440 - 3440
Background: Tyrosine kinase inhibitor (TKI) therapy has led to phenomenal improvement in overall survival for patients with CML. Since TKI therapies were... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5068 - 5068
Background: Relapsed/Refractory AML (RR-AML) represents an area in urgent need for new treatments, particularly among patients ineligible for intensive... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5842 - 5842
Background: Digital platforms designed for medical specialists have potential to enhance the delivery of continued education for healthcare professionals... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5430 - 5430
Background: The myelodysplastic syndromes (MDS) represent heterogeneous disorders with varied clinical courses. The major prognostic tool in MDS is the IPSS-R,... 
Journal Article
BMC Cancer, ISSN 1471-2407, 04/2018, Volume 18, Issue 1, pp. 359 - 8
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 3837 - 3837
Background: Outcomes of patients with AML have remained poor despite the availability of cytotoxic chemotherapy, hypomethylating agents (HMAs) and targeted... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.